The incidence and outcome of septic shock patients in the absence of early-goal directed therapy by Ho, Benjamin CH et al.
Open Access
Available online http://ccforum.com/content/10/3/R80
Page 1 of 7
(page number not for citation purposes)
Vol 10 No 3 Research
The incidence and outcome of septic shock patients in the 
absence of early-goal directed therapy
Benjamin CH Ho1, Rinaldo Bellomo1, Forbes McGain1, Daryl Jones1, Toshio Naka1, Li Wan1 and 
George Braitberg2
1Department of Intensive Care, Department of Medicine, University of Melbourne, Melbourne, Australia
2Department of Emergency Medicine, Austin Hospital, Melbourne, Australia
Corresponding author: Rinaldo Bellomo, rinaldo.bellomo@austin.og.au
Received: 13 Mar 2006 Accepted: 18 Apr 2006 Published: 16 May 2006
Critical Care 2006, 10:R80 (doi:10.1186/cc4918)
This article is online at: http://ccforum.com/content/10/3/R80
© 2006 Ho et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction The purpose of the present study was to measure
the incidence and outcome of septic patients presenting at the
emergency department (ED) with criteria for early goal-directed
therapy (EGDT).
Method This hospital-based, retrospective, observational study
using prospectively collected electronic databases was based
in a teaching hospital in Melbourne, Australia. We conducted
outcome-blinded electronic screening of patients with infection
admitted via the ED from 1 January 2000 to 30 June 2003. We
obtained data on demographics, laboratory and clinical features
on admission. We used paper records to confirm electronic
identification of candidates for EGDT and to study their
treatment. We followed up all patients until hospital discharge or
death.
Results Of 4,784 ED patients with an infectious disease
diagnosis, only 50 fulfilled published clinical inclusion criteria for
EGDT (EGDT candidates). Of these patients, 37 (74%)
survived their hospital admission, two (4%) died in the ED, eight
(16%) died in the intensive care unit and three (6%) died in the
ward. After review of all ward cardiac arrests and non-NFR ('not
for resuscitation') ward deaths, we identified a further two
potential candidates for EGDT for an overall mortality of 28.8%
(15 out of 52 patients). Analysis of treatment showed that twice
as many (70%) of the EGDT candidates received vasopressor
therapy in the ED, and their initial mean central venous pressure
(10.8 mmHg) was almost twice that in patients from the EGDT
study conducted by Rivers and coworkers.
Conclusion In an Australian teaching hospital candidates for
EGDT were uncommon and, in the absence of an EGDT
protocol, their mortality was lower than that reported with EGDT.
Introduction
Patients with the clinical diagnosis of an infectious disease are
frequently admitted to hospital from the emergency depart-
ment (ED). Some of these patients have severe sepsis or sep-
tic shock and require admission to the intensive care unit
(ICU). Rivers and coworkers [1] recently reported that resus-
citation with an approach described as early goal-directed
therapy (EGDT) reduced mortality in such patients from
46.5% to 30.5%. Accordingly, EGDT, if widely applicable and
generalizable, potentially could save thousands of lives world-
wide. In response to this evidence, many centers have consid-
ered the introduction of EGDT to the care for their ED patients
presenting with both severe sepsis and appropriate criteria for
EGDT.
However, no information exists outside the single center in
which the EGDT study was conducted. In particular, there is
no information on how frequently such patients attend the ED
in different health care systems, institutions, or geographical
settings, and on their mortality outside the single institution in
which the EGDT trial was conducted. Such information would
be of value in improving our understanding the external validity
of the EGDT approach, assessing the possible workload for a
sepsis team, clarifying the 'therapeutic opportunity' associated
with EGDT and helping other investigators to power multi-
center randomized controlled trials of EGDT. The US National
Institutes of Health recently funded one such study (ProC-
ESS), which will conduct preliminary feasibility work prior to
randomization.
APACHE = Acute Physiology and Chronic Health Evaluation; BE = base excess; ED = emergency department; EGDT = early goal-directed therapy; 
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In our institution, EGDT has not yet been implemented but was
considered as an important quality improvement measure.
Accordingly, we sought to obtain institution-specific baseline
information relevant to EGDT and studied the incidence and
outcome of septic patients admitted to hospital through our
ED who fulfilled criteria for EGDT. Here we report our findings.
Materials and methods
Study population
This study was approved the Human Research Ethics Com-
mittee of the Austin Hospital. The need for informed consent
was waived because the study required no intervention and no
breach of privacy or anonymity. The Austin Hospital is an
urban, academic, teaching, tertiary care hospital with 800
beds that is based in the city of Melbourne, Australia. The ED
of the Austin Hospital has approximately 40,000 patient visits
per year, with approximately 12,000 of these resulting in hos-
pital admission.
We included all adult patients (age >18 years) who were
admitted to the Austin Hospital from the ED with an admission
ICD-10 (International Classification of Disease version 10)
diagnostic code of an infectious condition (Table 1). We stud-
ied a period of 3.5 years (from 1 January 2000 through 30
June 2003), which preceded and overlapped with the timing
of the EGDT study conducted by Rivers and coworkers [1].
We called this group the 'primary cohort'. The selection proc-
ess was blinded to outcome.
From this primary cohort we then identified patients with
severe sepsis or septic shock by selecting all patients who
died in the ED, required care in the ICU (including all patients
who died in the ICU), required care in the high dependency
unit (HDU; including all patients who died in the HDU), died in
the general ward from cardiac arrest, and died in the general
wards without a 'not for resuscitation' (NFR) order. We called
this the 'secondary cohort'.
Figure 1
Study profile Study profile. BE, base excess; ED, emergency department; EGDT, early goal-directed therapy; HDU, high dependency unit; ICU, intensive care 
unit; IV, intravenous; NFR, not for resuscitation; SIRS, systemic inflammatory response syndrome.Available online http://ccforum.com/content/10/3/R80
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For this secondary cohort we reviewed all charts and elec-
tronic ED records. This allowed us to identify patients who met
the following EGDT criteria while in the ED (as described by
Rivers and coworkers [1]): two of four criteria for the systemic
inflammatory response syndrome [2] and a systolic blood
pressure no higher than 90 mmHg (after a crystalloid fluid
challenge of 20–30 ml/kg body weight over 20–30 minutes).
We recorded these patients as meeting the 'clinical criteria' for
Table 1
Diagnoses of infections by ICD-10 codes for patients admitted from the emergency department
Code Diagnosis Number
A09A Enteritis, presumed infectious. Excludes noninfectious enteritis K52.9 21
A09B Gastroenteritis, presumed infectious. Excludes noninfectious 
gastroenteritis K52.9
98
A09C Diarrhoea. Excludes diarrhoea noninfectious K52.9 32
A41.8 Septicaemia 278
A41.9 Septic shock 45
A49.9 Bacteraemia (excludes that with sepsis, see Septicaemia) 16
A86 Encephalitis, viral (includes viral meningoencephalitis/viral 
encephalomyelitis)
7
J02.0 Pharyngitis, acute streptococcal (includes sore throat) 9
J03.9 Tonsillitis, acute 36
J18.0 Bronchopneumonia 434
J18.1 Pneumonia, lobar 928
J20.9 Bronchitis, acute 24
J22A Acute lower respiratory tract infection 500
J22B Lower respiratory tract infection, chest 82
J69.0 Bronchopneumonia, aspiration 119
K04.7 Abscess, dental 16
K22.3 Perforation of oesophagus 2
K27.1 Peptic ulcer, acute, with perforation 14
K61.0 Abscess, perianal or anal 67
K81.9 Cholecystitis 165
L03.9 Cellulitis, skin, any site. Excludes cellulitis of finger or toe L03.01/
L03.02
541
M00.99 Arthritis, infective 36
N12 Pyelonephritis 124
N30.9 Cystitis 1
N39.0A Bacteriuria/urinary tract infection (UTI) 230
N39.0B Urinary sepsis 178
N39.0C Urinary tract infection 226
N45.9C Epididymitis/orchitis/epidymo-orchitis 33
R09.1 Pleurisy 23
R10.0 Severe abdominal pain/acute abdomen 90
R19.8 Perforated viscous/ruptured viscous 31
R50.9 Fever/pyrexia of unknown origin (PUO) 378
Total 4,784
ICD-10, International Classification of Disease version 10.Critical Care    Vol 10 No 3    Ho et al.
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EGDT. However, in the EGDT study [1] patients could also be
randomized because of a lactate concentration above 4 mmol/
l (biochemical criterion for EGDT). Accordingly, by linking with
the central laboratory electronic database, we also identified
all patients from the primary cohort with a lactate concentra-
tion above 4.0 mmol/l. In those patients in whom the lactate
concentration was not measured, we used a base excess (BE)
of -4 mEq/l or worse or a bicarbonate below 20 mmol/l as sur-
rogates for a lactate of 4 mmol/l. To ensure that no patients
were missed who might have had a lactate concentration
above 4.0 mmol/l, we conducted a further 'tertiary analysis'
using a BE of -3 mEq/l or worse as the cut off point. Finally, we
conducted a fourth-round analysis using a BE of -2 mEq/l or
worse as the selection criterion.
All patients included at each step as potential candidates for
EGDT were defined as meeting the 'laboratory criteria' for
EGDT and added to the secondary cohort. Patients were, of
course, excluded from our study if they fulfilled one or more of
the exclusion criteria described in the EGDT trial [1]. This
selection process is summarized in the study profile given in
Figure 1.
For all patients in the secondary cohort medical records were
retrieved to obtain data on history, vital signs, laboratory
results, treatment and details of outcome using the central lab-
oratory database, the ICU patient information database, the
hospital admissions and discharges database (which records
all deaths) and the hospital cardiac arrests database. The
severity of illness of the study patients was calculated using
the Acute Physiology and Chronic Health Evaluation
(APACHE) II score [3] and the Simplified Acute Physiology
Score II [4].
Data were compiled and analyzed using Microsoft Excel 2002.
Additional statistical analysis was performed using Statview,
version 4.57 (Abacus Concepts, Inc., Berkeley, CA, USA).
Results for descriptive statistical analysis are expressed as
means with standard deviation. P < 0.05 was considered sta-
tistically significant.
Results
Patients
Over the study period, 4,784 patients were admitted via the
ED with a diagnosis of an infectious disease or probable infec-
tious disease. From this cohort, 4,556 patients were excluded
from further analysis because they did not die or go on to the
ICU or the HDU. This left 228 candidates for EGDT (Figure 1).
Of these, 23 had pre-ED NFR orders and were excluded, in
accordance with the exclusion criteria employed by the EGDT
trial [1]. There were a further 41 septic patients who required
immediate (within 2 hours) surgery. Because immediate sur-
gery was an exclusion criterion of the EGDT trial, these
patients were also excluded. Three patients met other exclu-
sion criteria, as described in the EGDT study. Another 10
patients had NFR orders assigned to them in the ED after dis-
cussion with the family and primary unit. These patients were
also excluded from analysis, as described in the EGDT trial.
Two patients remained who died in the ED without NFR orders
and met the study criteria. They were included in the outcome
analysis. A further 99 patients had sepsis, were admitted to
ICU or HDU but never met the clinical EGDT study criteria for
severe sepsis or septic shock. This left only 50 patients with
sepsis who met the clinical study criteria and none of the
exclusion criteria. Importantly, no patients with severe sepsis
were directly admitted to the ICU from another hospital during
this time and no patients with severe sepsis were transferred
from the ED of our hospital to another hospital during the study
period. Thus, a total of 52 (50 admitted to the ICU/HDU + 2
who died in the ED without NFR orders) patients fulfilled the
clinical study criteria for severe sepsis or septic shock used in
the EGDT study [1] and none of its exclusion criteria.
However, during the study period, there were also 104 cardiac
arrests and/or non-NFR deaths in the general wards. Of these,
only two patients had been admitted via the ED with infection.
Both were older than 80 years and had multiple co-morbidities
(ischaemic heart disease, chronic obstructive airways disease,
asbestosis diabetes, chronic renal failure). They did not appear
to fulfill either clinical or BE or bicarbonate criteria for EGDT
while in ED.
Treatment and outcomes
The average time spent in the ED by the EGDT candidates
before hospital admission was 8.5 ± 5.3 hours (median 7.9
hours, range 2 to 26.9 hours). The mean total hospital length
of stay from presentation at the ED was 13.3 ± 12.2 days
(median 9.6 days, range 0.1 to 64.8 days).
Three of these patients were initially admitted to the general
ward before being transferred to the ICU. Of the 17 patients
admitted to the HDU, three were subsequently transferred to
the ICU after being in the HDU for 6 to 23 hours. The mean
HDU LOS for these 17 patients was 2.4 ± 3.8 days (median
1.0 days, range 0.2 to 15.8 days). The number of patients
admitted directly to the ICU was 28. The mean ICU length of
stay for these 34 patients (including the six patients who were
transferred into it) was 3.2 ± 3.4 days (median 2.0 days, range
0.3 to 14.6 days).
The clinical and laboratory findings during the first 6 hours in
the ED are summarized in Table 2. Four patients had temper-
atures below 36.0°C and 31 had temperatures greater than or
equal to 38.0°C. Of the 49 patients in whom blood culture was
performed, 17 had positive blood cultures. Of the 41 patients
in whom urine culture was performed, seven were positive;
and of the 22 patients in whom sputum or tracheal aspirate
culture was performed, five were positive. Table 3 summarizes
their primary sources of infection.Available online http://ccforum.com/content/10/3/R80
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While in the ED, among the 50 patients admitted to hospital,
39 (78%) patients had an intra-arterial catheter inserted. For
the 36 (72%) patients who had a central venous catheter
inserted in the ED, the mean initial central venous pressure
was 10.8 ± 4.7 mmHg (median 11 mmHg, range 2–20
mmHg). Only one patient (2%) received a blood transfusion.
Antibiotics were started within 6 hours in 45 (90%) patients.
Vasopressor agents were started in the ED in 35 (70%)
patients. Mechanical ventilation was commenced in the ED in
12 (24%) patients. Another three patients subsequently
required mechanical ventilation in the ICU.
Of these 52 study patients, 37 (71.2%) survived hospital
admission, two (3.8%) died in the ED, eight (15.3%) died in
the ICU and six (11.5%) died in the ward.
Using the lactate criterion, an additional single patient was
found to have been a candidate for EGDT (lactate of 4.8
mmol/l) who had not been identified using the clinical criteria.
This patient was a 20-year-old female with pyrexia of unknown
cause. She was admitted to a general ward and survived to
hospital discharge.
Using a BE of -4 mEq/l or worse or a bicarbonate below 20
mmol/l as markers for an elevated lactate concentration when
lactate was not measured, 26 patients were found who might
also have been candidates for EGDT. Of these 26 patients, 23
survived to hospital discharge. The three who died had NFR
orders. Using a BE of -3 mEq/l or worse, a further four patients
were identified who might have been candidates for EGDT. Of
these, three survived to hospital discharge. The one who died
had a NFR order. Using a BE of -2 mEq/l or worse, an addi-
tional eight patients were identified. Of these, six survived to
hospital discharge. The two who died had NFR orders.
Discussion
We conducted a study of patients presenting to the ED of a
teaching hospital in Melbourne, Australia with severe sepsis or
septic shock and who met clinical criteria for EGDT [1]. We
measured the incidence of candidacy for EGDT and mortality
rates in such patients. We found that approximately 1.0% of
patients with a diagnosis of infection were candidates for
EGDT. In the absence of EGDT, hospital mortality in these
patients was 30.2%. We further made comprehensive
attempts to identify any other patients who might have had an
elevated lactate in isolation as the sole criterion for EGDT.
After their inclusion, the incidence of the syndrome (reflected
by candidacy for EGDT) was still only 1.6% and its non-NFR
mortality lower. These findings are relevant to other institutions
considering the application of EGDT and to the powering of
future randomized controlled trials.
It must be borne in mind that this (like the EGDT trial [1]) is a
single centre study. Thus, our observations might not apply to
other centres. However, this is precisely the point and major
finding of our investigation, namely that in different health care
systems, geographical settings and institutions the syndrome
described in the EGDT trial may be relatively uncommon and
carry a different mortality. However, we note that our findings
are concordant with those reported by Shapiro and coworkers
[5]. Those American investigators identified ED patients at risk
for infection, as indicated by blood culture order. Of the 2,070
patients so identified, only 52 (2.5%) had septic shock
(defined as severe sepsis plus persistent hypotension after an
initial fluid challenge of 20–30 ml/kg), with a 28-day hospital
mortality rate of 26.9%. This mortality rate is similar to that in
our study. Using two electronic reference libraries and broad
search strategies, we could not find any other studies of the
outcome of ED patients with severe sepsis or septic shock.
Our study is retrospective, with all the limitations inherent to
such studies. However, we used a specific and reproducible
Table 2
Clinical and laboratory findings in the emergency room
Parameter Value
Highest heart rate 119 ± 25 beats/minute
Highest respiratory rate 31.7 ± 8.9 breaths/minute
Mean APACHE II score 19.8 ± 7.8
Mean SAPS II score 40.2 ± 16.1
Mean white cell count 13.2 ± 10.1 × 109/l
Mean haemoglobin 12.4 ± 2.2 g/dl (lowest value: 
7.8 g/dl)
Mean platelet count 217 ± 218 × 109/l
Mean [urea] 13.6 ± 7.6 mmol/l
Mean [creatinine] 222 ± 218 µmol/l
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, 
Simplified Acute Physiology Score.
Table 3
Primary source of infection in patients admitted to the ICU/
HDU with clinical criteria for EGDT
Diagnosis Number of patients
Lower respiratory tract infection 19
Unknown source 10
Urinary tract infection 9
Abdominal infection 4
Central nervous system infection 3
Skin/muscle infection 3
Vascular line infection 1
Dental infection 1
EGDT, early goal-directed therapy; HDU, high dependency unit; ICU, 
intensive care unit.Critical Care    Vol 10 No 3    Ho et al.
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strategy to identify patients for inclusion, making it possible for
other investigators to confirm or refute our findings elsewhere.
Furthermore, the data used were electronically and prospec-
tively collected and stored in various hospital databases, and
were not amenable to bias or manipulation. Some candidates
for EGDT might have been admitted to the general ward and
missed by our identification process. However, because of our
hospital's policy, all patients requiring vasopressor therapy or
who remain hypotensive despite fluid resuscitation are admit-
ted to the ICU or HDU in our institution. If any such patients
were ever admitted to the general wards, it would be for palli-
ative care only. This would have excluded them from allocation
to EGDT. Nonetheless, we studied all deaths to ensure that no
possible EGDT candidates who died would be missed. Only
two such patients were identified who had died in the ward
and were not NFR. These patients did not fulfill the clinical
EGDT trial criteria and their base deficit was not greater than
-3 mEq/l. Nonetheless, according to study protocol, these two
patients who died were added to the overall cohort.
We might have missed patients who did not fulfill clinical crite-
ria for EGDT but who would have been randomized to EGDT
on the basis of an isolated lactate concentration above 4
mmol/l. (We note that the EGDT trial did not report how many
such patients were randomized on the basis of an elevated lac-
tate only.) However, only one patient had a lactate above 4
mmol/l in isolation. That patient survived. Because lactate was
not routinely measured in all septic patients admitted to hospi-
tal, we used BE and bicarbonate as surrogates to identify
patients who might have had an isolated yet unmeasured high
lactate level. We thus identified several such patients and
included them in our analysis. Their inclusion further lowered
the mortality rate and only slightly increased the number of
possible candidates for EGDT. We note that our protocol was
biased toward inflating mortality by identifying all deaths
among the initial cohort and potentially missing patients who
fulfilled the clinical or biochemical criteria for EGDT but went
on to be treated in the ward and did not die.
Some patients might have had severe sepsis or septic shock
but were not identified by the ED ICD coding, medical and
nursing notes, and hourly observations. This is unlikely. How-
ever, even if this were true, these patients would not have been
candidates for EGDT, because such treatment requires recog-
nition of sepsis as the cause of the patient's illness. We might
have incorrectly classified patients as having severe sepsis or
septic shock when in fact they were less ill. This is essentially
impossible because the search criteria were prospectively
determined, numerical and objective in nature, and could only
be verified with independently recorded observations or labo-
ratory findings.
The low incidence of the syndrome targeted by EGDT in our
hospital may reflect a particular health care system, geograph-
ical setting, or institution. However, this is the very point we
wish to make – each hospital must assess its characteristics
with regard to this syndrome and its outcome. We note, how-
ever, that the incidence found in our hospital is concordant
with that reported by Shapiro and coworkers [5]. We also note
that our hospital is typical of a teaching hospital in any large
Australian city. However, the Australian health care system is
quite different from the American system and offers free
access to medical care to all patients, irrespective of health
insurance status. Some patients with sepsis might present
much later in the US system because concern about lack of
health insurance and associated cost of care.
The low mortality in our cohort might reflect a group that was
less critically ill. This once again supports our point about the
need for each institution to assess its own population. None-
theless, the mean APACHE II score was 19.8 versus 20.4 in
the EGDT study; the percentages of patients with severe sep-
sis and septic shock in our study were 44.0% and 56.0%,
respectively, compared with 48.7% and 51.3% in the control
group of the EGDT study. Furthermore, our mortality rate is
concordant with the findings reported by Shapiro and cowork-
ers [5] and those of the recent PROWESS trial [6], which
reported 30.8% mortality in septic patients randomly assigned
to placebo (pre-randomization APACHE II score 25). The mor-
tality reported in the control arm of the EGDT trial, however, is
discordant with these findings.
Many of our patients were assigned to palliative care only.
Some of these patients might have been considered for active
therapy elsewhere and received active intervention in the
EGDT study. Such patients might have died more frequently
and thus led to a high mortality. However, if this were the case
then this difference would provide further proof of the need to
assess more broadly the generalizability of the EGDT
approach.
Finally, the reported advantages of EGDT might not reflect the
style of fluid and haemodynamic management per se [7-9] but
rather the general consequences of early involvement of expert
physicians in the management of severe sepsis and septic
shock. Early experienced team intervention, rather than spe-
cific interventions targeted at high superior vena cava oxygen
saturation, may be the variable within the EGDT intervention
bundle that improves survival. If this is so, then in the model of
care operative at our institution (formal training in emergency
medicine, senior emergency medicine staff rapidly involved in
patient care 24 hours/day, early co-management and 'closed'
ICU system) such advantages might already be realized. The
intervention rates of central line insertion in 78% of patients,
arterial cannulation in 72% of patients, and antibiotic adminis-
tration in the first 6 hours in 90% of cases all support this view.
More importantly, the initial mean central venous pressure
CVP of above 10 mmHg in our patients (compared with
between 5 and 6 mmHg in the EGDT study [1]) and a 70%
rate of vasopressor drug administration (compared withAvailable online http://ccforum.com/content/10/3/R80
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approximately 30% in the EGDT study) suggest that more
aggressive and prompt resuscitation was already taking place
routinely in our hospital even before the publication of the
EGDT protocol.
Conclusion
In a teaching hospital in Australia, the number of candidates
for EGDT was low, mortality lower than that reported with
EGDT and treatment already potentially more aggressive and
prompt. These observations provide useful information for the
powering of planned multicentre randomized controlled trials
of EGDT. They now require confirmation in other geographical
and health care settings.
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Key messages
•  Of more than 4,700 patients with an infectious disease 
diagnosis, little more than 1% fulfilled criteria for EGDT.
•  Among patients who were candidates for EGDT, 70% 
were treated with vasopressor drugs.
•  For patients who were candidates for EGDT, the mortal-
ity rate was 28.8%.
•  The incidence of candidacy for EGDT may be lower 
than widely believed and outcome may be better than 
estimated, even in the absence of EGDT; this informa-
tion is important in that it may help to design planned 
multicentre trials of EGDT.